Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity

Condition:   Coronavirus Disease 2019 Intervention:   Biological: Recombinant new coronavirus vaccine (CHO cell) group Sponsor:   Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials